Prince Street
SlowingNew York, NYBiotechnology, Healthcare, HardwareLast fund filed September 2008
10 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Prince Street Fund | September 2008 | Indefinite | $324M | 34 |
| Prince Street Fund | May 2001 | Indefinite | $256M | 127 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
10 partners are named across this firm’s filings, 10 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Thomas Davis | Slowing | Food & agriculture, AI & machine learning, Biotech & pharma | 10 | 1 |
| Anne Wynne | Quiet | None listed | 0 | 0 |
| Daniel Cochran | Quiet | None listed | 0 | 0 |
| David Halpert | Quiet | None listed | 0 | 0 |
| Edward Simnett | Quiet | Fintech, Mobility & transportation | 2 | 0 |
| Michael Wasserman | Quiet | Medical devices, Biotech & pharma, Fintech | 6 | 0 |
| Nicholas Hofgren | Quiet | None listed | 0 | 0 |
| Peter McKown | Quiet | None listed | 0 | 0 |
| Wasserman Michael | Quiet | None listed | 0 | 0 |
| William Wang | Quiet | Education | 1 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Prince Street’s own portfolio companies, based on 19 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Prince Street’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| 7wire Ventures | 1 | CLARIFY MEDICAL |
| Advent Life Sciences | 1 | Moximed |
| Hyperplane | 1 | Notarize |
| Lightstone Singapore | 1 | Moximed |
| Lightstone Ventures | 1 | Moximed |
| Longitude 103.8 East | 1 | Orbus Therapeutics |
| Longitude Capital | 1 | Orbus Therapeutics |
| Longitude Prime | 1 | Orbus Therapeutics |
| NEA | 1 | Moximed |
| Polaris Partners | 1 | Notarize |
| SV Life Sciences | 1 | CLARIFY MEDICAL |
| Venbio Select | 1 | Orbus Therapeutics |
| Versant Venture Capital | 1 | NEUWAVE MEDICAL |
A shared board seat: a company where filings name a Prince Street partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.